Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse

Martina Gerotto, Francesca Dal Pero, Gladis Bortoletto, Alessia Ferrari, Roberta Pistis, Giada Sebastiani, Stefano Fagiuoli, Stefano Realdon, Alfredo Alberti

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background/Aims: Around 15-25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA). Methods: Two hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6-8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal. Results: Among 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5%) were found HCV-RNA positive by TMA. Twenty-two of them, (96%) were PCR-relapsers after therapy withdrawal, compared to only 14% of the 182 TMA negative patients (P

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalJournal of Hepatology
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Ribavirin
Viremia
Hepatitis C
Recurrence
Polymerase Chain Reaction
RNA
Therapeutics
Chronic Hepatitis C
Appointments and Schedules
Injections
Serum

Keywords

  • HCV relapsers
  • HCV-RNA
  • Hepatitis C
  • PEG-IFN plus ribavirin
  • TMA

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. / Gerotto, Martina; Dal Pero, Francesca; Bortoletto, Gladis; Ferrari, Alessia; Pistis, Roberta; Sebastiani, Giada; Fagiuoli, Stefano; Realdon, Stefano; Alberti, Alfredo.

In: Journal of Hepatology, Vol. 44, No. 1, 01.2006, p. 83-87.

Research output: Contribution to journalArticle

Gerotto, M, Dal Pero, F, Bortoletto, G, Ferrari, A, Pistis, R, Sebastiani, G, Fagiuoli, S, Realdon, S & Alberti, A 2006, 'Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse', Journal of Hepatology, vol. 44, no. 1, pp. 83-87. https://doi.org/10.1016/j.jhep.2005.08.016
Gerotto, Martina ; Dal Pero, Francesca ; Bortoletto, Gladis ; Ferrari, Alessia ; Pistis, Roberta ; Sebastiani, Giada ; Fagiuoli, Stefano ; Realdon, Stefano ; Alberti, Alfredo. / Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. In: Journal of Hepatology. 2006 ; Vol. 44, No. 1. pp. 83-87.
@article{5b8510fe1ad2475a8d0a961c54822058,
title = "Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse",
abstract = "Background/Aims: Around 15-25{\%} of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA). Methods: Two hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6-8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal. Results: Among 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5{\%}) were found HCV-RNA positive by TMA. Twenty-two of them, (96{\%}) were PCR-relapsers after therapy withdrawal, compared to only 14{\%} of the 182 TMA negative patients (P",
keywords = "HCV relapsers, HCV-RNA, Hepatitis C, PEG-IFN plus ribavirin, TMA",
author = "Martina Gerotto and {Dal Pero}, Francesca and Gladis Bortoletto and Alessia Ferrari and Roberta Pistis and Giada Sebastiani and Stefano Fagiuoli and Stefano Realdon and Alfredo Alberti",
year = "2006",
month = "1",
doi = "10.1016/j.jhep.2005.08.016",
language = "English",
volume = "44",
pages = "83--87",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse

AU - Gerotto, Martina

AU - Dal Pero, Francesca

AU - Bortoletto, Gladis

AU - Ferrari, Alessia

AU - Pistis, Roberta

AU - Sebastiani, Giada

AU - Fagiuoli, Stefano

AU - Realdon, Stefano

AU - Alberti, Alfredo

PY - 2006/1

Y1 - 2006/1

N2 - Background/Aims: Around 15-25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA). Methods: Two hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6-8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal. Results: Among 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5%) were found HCV-RNA positive by TMA. Twenty-two of them, (96%) were PCR-relapsers after therapy withdrawal, compared to only 14% of the 182 TMA negative patients (P

AB - Background/Aims: Around 15-25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detected in these cases by Transcription-Mediated Amplification (TMA). Methods: Two hundred and ninety-two consecutive patients (143 HCV-1, 82 HCV-2, 56 HCV-3 and 11 HCV-4) were prospectively treated with a standard schedule of Peg-IFNα 2b plus ribavirin combination and end-of-therapy response was assessed by conventional PCR using 2 protocol serum samples obtained 6-8 h before the last two scheduled weekly injections of Peg-IFN. PCR negative samples were re-tested by TMA and the results were then correlated with the virological outcome after therapy withdrawal. Results: Among 208 patients who were repeatedly HCV-RNA negative by PCR at the end-of-therapy, 26 (12.5%) were found HCV-RNA positive by TMA. Twenty-two of them, (96%) were PCR-relapsers after therapy withdrawal, compared to only 14% of the 182 TMA negative patients (P

KW - HCV relapsers

KW - HCV-RNA

KW - Hepatitis C

KW - PEG-IFN plus ribavirin

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=28844432020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844432020&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2005.08.016

DO - 10.1016/j.jhep.2005.08.016

M3 - Article

VL - 44

SP - 83

EP - 87

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -